non responder to semaglutide tirzepatide responders Are YOU a Slow/Non-Responder GLP-1's? TrimRX Are YOU a Slow/Non-Responder to – Non-responders: Not losing weight on

It is the active pharmaceutical ingredient in Novo Nordisks Ozempic (FDA-approved 2017 for Type 2 diabetes), Wegovy (FDA-approved 2021 for chronic weight management in adults with obesity, and 2024 expanded for cardiovascular risk reduction in adults with overweight/obesity and established cardiovascular disease), and Rybelsus (oral form, Type 2 diabetes)

A physician-supervised program ensures you receive a regulated, effective, and safe product

The treatment of type 2 diabetes with GLP-1s has been a proven method since 2005

your PlexusDx provider monitors tolerance during monthly check-ins and can adjust your dose if needed

Study drug was permanently discontinued due to an adverse event in 15.5% of semaglutide tablets-treated patients and 11.6% of placebo-treated patients